Home / Business and Economy / Surgical Tech Sees 5% Sales Growth, Lifts Outlook
Surgical Tech Sees 5% Sales Growth, Lifts Outlook
6 Aug
Summary
- Net sales grew 5% in constant currency, reaching $109 million for spinal products.
- Limb reconstruction sales saw an impressive 11% increase year-over-year.
- Full-year adjusted EBITDA guidance was raised to $95 million - $98 million.
The company announced a 5% pro forma constant currency net sales growth compared to the previous year. Global Spinal Implants, Biologics, and Enabling Technologies contributed $109 million to net sales, marking a 4% increase.
Therapeutic Solutions recorded $64.2 million in net sales, a 3% rise. Global Limb Reconstruction sales demonstrated robust growth, increasing by 11% year-over-year to $37.7 million. Global Spine Fixation sales rose 10% on a constant currency basis.
Biologics net sales were approximately flat, showing improvement from previous declines. Non-GAAP Adjusted Gross Margin stood at 71.7%, affected by an unfavorable geographic mix. Adjusted EBITDA for the second quarter was $20.1 million.
The company has raised its full-year adjusted EBITDA guidance to between $95 million and $98 million. Total cash on hand is $104.4 million. Full-year 2026 net sales are projected to be between $845 million and $855 million.
